Diabetes
57 articles on Diabetes, written by Shotlee and medically reviewed for clinical accuracy.
Beyond Weight Loss: Do GLP-1 Drugs Impact Mental Health?
New research is exploring the surprising potential of GLP-1 receptor agonists, known for their role in diabetes and weight management, to also influence mental well-being. This article delves into the latest findings and what they mean for patients.
7 min read
Beyond BMI: Why Mounjaro Eligibility is More Complex Than You Think
Many assume BMI is the sole determinant for Mounjaro prescriptions, but the reality is far more nuanced. This article explores the comprehensive health criteria healthcare providers use to ensure safe and effective treatment.
6 min read
Beyond the Scale: Are GLP-1 Drugs Depleting Vital Nutrients?
While GLP-1 agonists are revolutionizing weight management, emerging research suggests a potential downside: nutrient deficiencies. This article delves into what the latest studies reveal about these vital nutrient gaps and how to address them.
6 min read
GLP-1 Medications and Supplement Needs: What You Should Know
As GLP-1 medications gain popularity for weight loss and diabetes management, understanding their impact on nutrient absorption is crucial. This article explores the link between these powerful drugs and the rising demand for supplements, offering insights from medical professionals and research.
6 min read
Generic Ozempic® Now Available in Canada: What You Need to Know
Apotex Inc. has launched Apo-Semaglutide Injection™, a generic version of Ozempic®, in Canada. This development brings a more affordable treatment option for type 2 diabetes management to Canadian patients and healthcare providers.
6 min read
GLP-1 Weight Loss Drugs: Usage Trends and What You Need to Know
The popularity of GLP-1 receptor agonists for weight management is soaring. This article delves into the latest trends, the science behind these medications, and essential considerations for patients and healthcare providers.
7 min read
GLP-1 Drugs and Hair Loss: What the Latest Research Reveals
New research suggests a connection between GLP-1 medications and temporary hair loss. Discover what this means for users of drugs like Ozempic, Wegovy, and Mounjaro, and how to navigate this common side effect.
8 min read
GLP-1 Drugs & Your Health: Beyond Weight Loss & 'Ozempic Breath'
GLP-1 agonists are revolutionizing weight management, but their effects extend far beyond the scale. This article delves into the science, the side effects like 'Ozempic breath,' and how these powerful medications are reshaping consumer habits and personal health journeys.
7 min read
Orforglipron: The New Oral GLP-1 Challenger in Weight Loss
A new daily pill, Orforglipron, is emerging as a significant contender in the weight loss and diabetes management space, offering a potential oral alternative to injectable GLP-1 medications. This article delves into its mechanisms, trial results, and what it means for the future of treatment.
7 min read
GLP-1 Medications and Hot Sauce: An Unexpected Link
The rise of GLP-1 medications has led to an unexpected surge in hot sauce sales. Explore the science behind altered taste perception and how it's influencing consumer choices.
6 min read
GLP-1 Medications & Weight Loss: What's Behind the Buzz?
The world of weight management has been significantly impacted by the emergence of GLP-1 receptor agonists. These medications, including popular drugs like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro), have garnered immense attention for their effectiveness in promoting weight loss and improving metabolic health. But what exactly are these drugs, how do they work, and what should individuals considering them know?
7 min read
Coverage Unlocks Semaglutide's Potential for Obesity & Diabetes
Semaglutide, a powerful GLP-1 receptor agonist, transforms obesity and diabetes management but requires robust insurance coverage to deliver full benefits. Gasoyan and Rothberg emphasize access hurdles like prior authorizations that delay treatment. Addressing these ensures equitable health improvements amid rising metabolic disorders.
2 min read
Lupin, Galenicum Sign Semaglutide Deal for 23 Countries
Lupin has signed a licensing and supply agreement with Galenicum for injectable Semaglutide in 23 countries. Galenicum handles development and manufacturing, while Lupin manages approvals and commercialization. This boosts access to the GLP-1 drug for diabetes and obesity treatment.
2 min read
Understanding GLP-1 Drugs for Weight Loss & Diabetes
GLP-1 drugs mimic natural hormones to reduce hunger, slow digestion, and control blood sugar, aiding weight loss and type 2 diabetes. In Malaysia, over 54% of adults are overweight or obese, prompting Health Ministry rollout for vulnerable groups in 2026. Understand benefits, risks, and safe use guidelines.
3 min read
Using medications like Ozempic prior to pregnancy could heighten your chances of...
New studies indicate that halting popular GLP-1 medications before or shortly after conception results in more substantial weight increases during pregnancy and elevated chances of serious issues for both mother and child. This comes amid rising usage of these drugs for weight management and diabetes control. Experts emphasize the need for further investigation into balancing pre-pregnancy advantages with post-discontinuation risks.
4 min read
Australia Issues Mental Health Alert for Weight-Loss Medications Like Ozempic
The Therapeutic Goods Administration (TGA) has issued new safety alerts concerning weight loss and diabetes medications. These warnings address potential mental health risks and reduced effectiveness of oral contraceptives when using drugs like Mounjaro.
2 min read
Ozempic and Weight Loss: An Examination with PhenQ Supplement Details
This article explores the use of Ozempic for weight loss, examining its effectiveness and safety. It also provides information on PhenQ as an alternative weight loss supplement.
8 min read
Natural Alternatives to Ozempic? 6 GLP-1 Rich Foods That Mimic the Effects
Weight loss medications such as Ozempic and Wegovy function by artificially elevating glucagon-like peptide 1 (GLP-1), a naturally occurring hormone that combats obesity and diabetes. Research indicates that certain foods can boost GLP-1 secretion, offering similar benefits without injections. These foods not only increase GLP-1 but also mimic its effects, aiding in weight management and overall health.
6 min read
Unseen Effects: Potential Impacts of GLP-1 Weight Loss Medications
GLP-1 medications, while effective for weight loss, can have various side effects. Understanding these potential impacts is crucial for informed decision-making and patient care. These medications affect different parts of the body, leading to diverse reactions based on individual physiology.
7 min read
GLP-1 Agonists Associated with Persistent Cough
A recent study has uncovered a potential connection between glucagon-like peptide-1 (GLP-1) receptor agonists and chronic cough in individuals managing type 2 diabetes. The research suggests that those using GLP-1 drugs were more prone to developing a persistent cough compared to those on alternative second-line treatments.
1 min read
Understanding GLP-1 Drugs: Weight Loss, Diabetes, and Side Effects
GLP-1 drugs are prescription medicines utilized to treat type 2 diabetes and aid weight loss under medical supervision. These medications work by imitating hormones responsible for controlling blood sugar and appetite. It is important to obtain them from regulated sources.
1 min read
A GLP-1 Drug Changed My Life: My Friends' Reactions Surprised Me
ShantaQuilette Carter-Williams shares her experience with GLP-1 medications after facing serious health issues. Her story highlights the transformative impact on her health, lifestyle, and relationships.
7 min read
Are Replicas of Ozempic and Wegovy Safe? Understanding Compounded GLP-1s
Compounded semaglutide medications are custom-made by compounding pharmacies, containing the active ingredient in Ozempic and Wegovy. However, they are not FDA-approved and carry potential risks. This article explains what you need to know about these alternatives.
12 min read
Why Indians Should Use Ozempic Cautiously: Understanding the Reason
With the introduction of new weight-loss and diabetes drugs like Ozempic in India, endocrinologists are emphasizing the need for cautious and medically supervised use. Concerns arise particularly for individuals with a 'thin-fat' phenotype, who may experience adverse effects.
3 min read
Research Suggests Diabetes Drug Ozempic May Offer Brain Protection
Recent research suggests that GLP-1 medications like Ozempic, typically used for diabetes and weight management, might also positively impact brain health. The study indicates a lower risk of epilepsy development in individuals with Type 2 diabetes using these drugs.
3 min read
Shannonside Region: State Invests Nearly €2.63 Million on Ozempic | Shannonside.ie
New data indicates that the State spent almost €2.63 million on the diabetes medication Ozempic in the Shannonside area from January to August of this year. Longford and Westmeath had the highest expenses, totaling about €1.4 million.
1 min read
Novo Nordisk India Introduces Ozempic, Considering Socio-Economic Factors | Briefs
Novo Nordisk has officially launched Ozempic in India, a once-weekly GLP-1 receptor agonist for adults managing uncontrolled type 2 diabetes. Intended as an add-on therapy to diet and exercise, Ozempic arrives as India grapples with a rapidly increasing diabetes burden and generalized obesity.
1 min read
Cleveland Clinic Reverses Type 2 Diabetes Using AI, Not GLP-1 Drugs
The Cleveland Clinic is utilizing an AI-powered approach to reverse type 2 diabetes. This innovative method focuses on creating a 'digital twin' of a patient's metabolism, leading to significant improvements in health markers and a reduction in medication dependence.
10 min read
Mounjaro by Eli Lilly Included in China's National Health Coverage for Diabetes
Mounjaro, a drug by Eli Lilly, is set to be added to China's state health insurance on January 1st. This inclusion could intensify competition among pharmaceutical companies. The move aims to improve access for China's large population.
1 min read
Feline Obesity Targeted by New 'Ozempic'-Like Drug Trial for Cats
A clinical trial is underway to test a new weight-loss treatment for cats using a drug class similar to Ozempic. The study, called MEOW-1, involves an implant administering medication to help overweight cats shed pounds.
3 min read
Weight Loss Meds Linked to Another Debilitating Adverse Effect
Weight loss medications, specifically GLP-1 receptor agonists, have been associated with an increased risk of chronic cough in individuals with type 2 diabetes. A recent study compared patients taking GLP-1s with those on other diabetes treatments, revealing a notable link between the drugs and persistent coughing.
5 min read
Dr. Reddy's Cleared by Delhi HC to Export Semaglutide Generics of Novo Nordisk
An Indian court has granted Dr. Reddy's Laboratories Ltd permission to manufacture and export generic versions of Novo Nordisk's diabetes and obesity medications. This decision comes before the global patent expirations in 2026. The ruling allows export to countries without patent protection.
2 min read
Ozempic, a Diabetes Medication, Slated for India Launch This Month
Novo Nordisk is set to introduce Ozempic in India, complementing their existing semaglutide product line. This launch occurs amidst strong competition from Eli Lilly's Mounjaro. The new medication may also be prescribed for other health conditions.
1 min read
Safety Alert Issued for Ozempic and GLP-1 Receptor Agonists by Watchdog
The Therapeutic Goods Administration (TGA) in Australia has released a safety warning concerning GLP-1 receptor agonists, including Ozempic. The alert highlights potential links to suicidal thoughts and the reduced effectiveness of oral contraceptives.
1 min read
Anticipating Large Profits: Ozempic Patent Expiration Sparks Indian Pharma Generics Race
With the impending expiration of the Ozempic and Wegovy patents, Indian pharmaceutical giants are gearing up for a significant opportunity in the generics market. Surging obesity rates across India are fueling the demand for affordable weight-loss solutions.
7 min read
Ozempic-like Medications: New Alert Issued Over Suicidal Thought Risk
Australia's Therapeutic Goods Administration (TGA) has issued a safety alert concerning Ozempic-style drugs and a potential connection to suicidal thoughts and behaviors. While a direct causal link hasn't been established, the TGA advises patients to immediately inform their healthcare provider if they experience any changes in mood or behavior.
4 min read
Berberine: Is This Supplement Truly 'Nature's Ozempic?' Experts Weigh In
Berberine, a compound found in several plants, has gained attention for its potential health benefits, including weight loss and blood sugar regulation. Some compare it to Ozempic, but experts caution about its effectiveness and safety compared to prescription medications.
4 min read
Ozempic 2.0? Exploring the Future of Weight Loss Medications
New weight loss drugs, potentially available in oral form, are under development by Eli Lilly and Novo Nordisk. These medications aim to manage type-2 diabetes and facilitate weight loss, potentially offering a more accessible and convenient alternative to current injectables.
4 min read
Novel Therapeutic Strategy Discovered for Nerve Impairment in Diabetes
A newly discovered mechanism explains limited nerve regeneration in diabetes, offering a promising therapeutic approach. Research demonstrates that targeting a specific signaling pathway can significantly improve nerve fiber regrowth in preclinical models.
3 min read
Tirzepatide & Semaglutide: Groundbreaking Heart Protection
A recent study has provided real-world evidence of the cardiovascular benefits of tirzepatide, a dual GLP-1 and GIP receptor agonist. The research compared tirzepatide to semaglutide and sitagliptin, finding similar heart protection.
2 min read
How Ozempic is Reshaping Thanksgiving Celebrations
The rise of GLP-1 medications is influencing how families celebrate Thanksgiving. With reduced appetites and changing dietary needs, many are finding innovative ways to balance tradition and health during the holidays.
3 min read
New Research Shows Hidden Caveats of Substantial Weight Loss from GLP-1 Medications Like Ozempic
Analyses of GLP-1 receptor agonists for weight management show clinically significant weight loss compared to placebo. However, long-term safety and potential side effects remain uncertain. Financial ties influencing study results are also a concern.
3 min read
Research Indicates Common Diabetes Medication May Inhibit Exercise Gains
New research suggests that a widely prescribed diabetes drug, metformin, might diminish some key advantages of exercise. The study indicated that individuals taking metformin experienced less improvement in blood sugar management and blood vessel performance compared to those who exercised without the medication.
4 min read
Sandoz CEO Predicts Semaglutide Biosimilars Entering Canadian Market in Q1 or Q2
Richard Saynor, CEO of Sandoz, expects biosimilars referencing semaglutide to be available in Canada in early 2026. This projection comes as Novo Nordisk's patent protection for the drug nears its end. Sandoz intends to capitalize on the commercial opportunity as soon as regulatory approval is granted.
3 min read
Novo Nordisk Reduces Wegovy Price Up to 37% in India Amid Mounjaro Competition
Novo Nordisk has reduced the price of Wegovy in India by as much as 37% to better compete with Eli Lilly's Mounjaro. This decision follows Mounjaro's rise to become the best-selling weight-loss medication in India by value.
2 min read
Ancient Chinese Medicine Berry Enhances Fat Metabolism in Mice with Diabetes
Research indicates that a berry utilized in traditional Chinese medicine can effectively restore healthy fat metabolism and enhance insulin sensitivity within a mouse model of diabetes. This finding suggests potential benefits for managing metabolic disorders.
4 min read
Cardioprotection Comparison: GLP-1 Drugs Show Similar Effects
Research comparing tirzepatide and semaglutide shows both medications reduce the risk of major cardiovascular events. The study highlights the early onset of cardioprotective effects, suggesting mechanisms beyond just weight loss. These findings support the integration of both agents into cardiovascular clinical practice.
2 min read
Real-World Data Highlights Heart Benefits of Diabetes Drugs Semaglutide and Tirzepatide
New research indicates that semaglutide and tirzepatide, drugs used for managing type 2 diabetes, exhibit heart-protective effects in real-world settings, mirroring findings from clinical trials. The study highlights the cardiovascular benefits these medications offer to patients in everyday clinical practice.
4 min read
Scientists Develop Method to Reprogram Pancreas for GLP-1 Production Without Ozempic
Scientists are exploring a way to enable the body's own production of glucagon-like peptide-1 (GLP-1), the hormone mimicked by weight-loss drugs. Two biotech startups are developing gene therapies to reprogram cells to produce GLP-1, potentially replacing regular injections.
3 min read
Novo Nordisk Stock: Factors Contributing to This Week's Decline | The Motley Fool
Shares of Novo Nordisk have decreased substantially. This drop is influenced by increased competition in the GLP-1 market and a revised outlook for future growth. The global drugmaker faces headwinds from competitors like Eli Lilly.
2 min read
Reduced Gestational Diabetes Risk Observed with GLP-1 Use Before Pregnancy
A retrospective cohort study revealed that women taking GLP-1 receptor agonists before pregnancy exhibited a lower incidence of gestational diabetes. However, the study also indicated a potentially higher risk of pre-eclampsia in this group. These findings warrant further investigation due to the small sample size and potential confounding factors.
4 min read
Mounjaro Weight-Loss Injection Now Top-Selling Drug in India
According to recent data, Mounjaro, a drug for obesity and diabetes developed by Eli Lilly, has emerged as India's top-selling pharmaceutical brand. The medication's sales have surpassed those of long-time market leader Augmentin.
3 min read
Novo Nordisk's Oral Wegovy Lowers Cardiovascular Risk Factors in Obesity Patients
The Phase III OASIS 4 trial revealed that Novo Nordisk's oral Wegovy (semaglutide) reduced cardiovascular risk factors in individuals with obesity. The study supports the drug's approval, showing improvements in C-reactive protein and serum triglycerides. Blood sugar control also improved among patients.
3 min read
Searching 'Weight' Can Yield Ozempic Results: A Drug Advertising Issue
A recent study highlights a potential issue in online drug advertising. Searching for terms like 'weight loss' can yield results for drugs like Ozempic, even if they are not FDA-approved for that specific purpose, raising concerns about misleading information.
3 min read
GLP-1s & Metabolic Health: New Research Links Peptide Therapy to Reduced Arthritis Risk
New research shows that GLP-1 receptor agonists, often used for diabetes and weight loss, may reduce the risk of certain types of arthritis. This blog post explores the potential benefits of this peptide therapy, offering actionable insights for improved health and wellness.
4 min read
GLP-1 Weight Loss Drugs and the Decline in Obesity: What You Need to Know
New data reveals a drop in obesity rates alongside increased use of GLP-1 weight-loss drugs. This blog explores the connection, offers actionable insights, and discusses the implications for your health and wellness journey.
4 min read
FDA Approves New Treatments: Oral Semaglutide & Lupus Nephritis Drug
The FDA has recently approved new treatments for two significant health challenges: cardiovascular risk reduction in type 2 diabetes and lupus nephritis. Learn about the potential benefits of these advancements and what they mean for patient care.
3 min read